PAX5 and non-small cell lung carcinoma: Furthermore, silencing of PAX5 could be reversed by demethylation treatment with the methylation transferase inhibitor 5‐Aza and histone deacetylase inhibitor TSA, suggesting that epigenetic modification is an important regulatory mechanism of PAX5 expression and activity in NSCLC.